Certain stocks are such poor bets that they are likely to lose ground even in bull markets.

ProKidney Corp. is a single-asset biotech with a dwindling cash position and an unproven lead therap

ProKidney Corp. (PROK) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.15) per share which missed the analyst cons

Stocks up, Dow Jones +100 points. AEVEX Corp shares rose 11.8% on $50m Air Force contract. Other big

US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol

Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Che

HC Wainwright & Co. analyst Joseph Pantginis reiterates ProKidney (NASDAQ:PROK) with a Buy an

ProKidney Corp. (PROK) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.14) per share which met the analyst consens

WINSTON-SALEM, N.C., May 15, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or

Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and ProKidney (NASDAQ: PROK - Get Free Report)

WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”

Shares of ProKidney Corp. (NASDAQ: PROK - Get Free Report) have earned a consensus rating of "Modera

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.14) per share which missed the analyst cons

ProKidney (NASDAQ: PROK - Get Free Report) will likely be releasing its Q4 2025 results before the m

PROK's main value driver is Rilparencel, which is now in a pivotal trial called PROACT 1. The FDA al

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o

HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on ProKidney (NASDAQ:PROK) wi

Shares of ProKidney Corp. (NASDAQ: PROK - Get Free Report) have been given a consensus recommendatio

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.12) per share which beat the analyst consen

WINSTON-SALEM, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o

WINSTON-SALEM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o

Tonix Pharmaceuticals (NASDAQ: TNXP - Get Free Report) and ProKidney (NASDAQ: PROK - Get Free Report

WINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o

WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney

WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o

As previously disclosed, on May 8, 2025, ProKidney Corp. (the "Company"), through its wholly

Chamath Palihapitiya is back with another SPAC. This time he's telling retail investors to stay

I rate ProKidney a buy due to promising Phase 2 data for rilparencel in advanced CKD, strong FDA ali

Chamath Palihapitiya is back with a new SPAC. Many investors will remember past SPACs the investor w

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.13) per share which beat the analyst consen

https://www.zacks.com/stock/news/2589077/prokidney-cp-prok-upgraded-to-strong-buy-what-does-it-mean-

UBS analyst Eliana Merle maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target

FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilpar

Guggenheim analyst Vamil Divan maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price

Guggenheim analyst Vamil Divan maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price

Citigroup analyst Yigal Nochomovitz maintains ProKidney (NASDAQ:PROK) with a Buy and raises the p

ProKidney shares are trading sharply higher Wednesday morning. The stock is gaining following a mark